Drug Detail

Information about CNF2024

Generic Name	CNF2024
IND	BIIB021
Brand Name (US)
Manufacturer	Biogen Idec
Drug Type	HSP90 inhibitor
Delivery	Oral
Approval Status	Discontinued?
Indications
Overall Strategy	KIT Protein Based
Strategy	Destroy KIT
Drug Category	HSP90 inhibitor

BIIB021 is an oral third-generation Hsp90 inhibitor and is manufactured by Biogen Idec. Phase II trials have started at Memorial Sloan-Kettering Cancer Center (New York, NY) and at the Mayo Clinic in Rochester, Minnesota. The phase II trial is specifically for GIST.

Phase I trials are underway in Scottsdale, AZ and in San Antonio, TX.

An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment (Phase II ClinicalTrials.gov)

Study of Oral CNF2024 in Advanced Solid Tumors (Phase I ClinicalTrials.gov)